Income Tax Expense (Benefit) in USD of Immunovant, Inc. from Q4 2018 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Immunovant, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q4 2018 to Q3 2025.
  • Immunovant, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2025 was $594K, a 662% increase year-over-year.
  • Immunovant, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2025 was $2.24M, a 704% increase year-over-year.
  • Immunovant, Inc. annual Income Tax Expense (Benefit) for 2024 was $891K, a 57.1% increase from 2023.
  • Immunovant, Inc. annual Income Tax Expense (Benefit) for 2023 was $567K, a 6200% increase from 2022.
  • Immunovant, Inc. annual Income Tax Expense (Benefit) for 2022 was $9K.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)

Immunovant, Inc. Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $2.24M $594K +$516K +662% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-10
Q2 2025 $1.73M $913K +$836K +1086% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-11
Q1 2025 $891K $584K +$352K +152% Jan 1, 2025 Mar 31, 2025 10-K 2025-05-29
Q4 2024 $539K $152K +$260K Oct 1, 2024 Dec 31, 2024 10-Q 2025-02-06
Q3 2024 $279K $78K -$376K -82.8% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-10
Q2 2024 $655K $77K +$88K Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-11
Q1 2024 $567K $232K +$1.22M Jan 1, 2024 Mar 31, 2024 10-K 2025-05-29
Q4 2023 -$656K -$108K -$495K -128% Oct 1, 2023 Dec 31, 2023 10-Q 2025-02-06
Q3 2023 -$161K $454K +$193K +73.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$354K -$11K -$363K -103% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $9K -$991K -$979K -8158% Jan 1, 2023 Mar 31, 2023 10-K 2025-05-29
Q4 2022 $988K $387K +$387K Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-12
Q3 2022 $601K $261K +$292K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $309K $352K +$393K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$84K -$12K +$67K +84.8% Jan 1, 2022 Mar 31, 2022 10-K 2023-05-22
Q4 2021 -$151K $0 +$367K Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-03
Q3 2021 -$518K -$31K -$71K -178% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-04
Q2 2021 -$447K -$41K -$89K -185% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-05
Q1 2021 -$358K -$79K -$20K -33.9% Jan 1, 2021 Mar 31, 2021 10-K 2022-06-08
Q4 2020 -$338K -$367K -$467K -467% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-04
Q3 2020 $129K $40K +$7K +21.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 $122K $48K +$25K +109% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $97K -$59K Jan 1, 2020 Mar 31, 2020 10-K 2021-06-01
Q4 2019 $100K +$92K +1150% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-16
Q3 2019 $33K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $23K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-12
Q4 2018 $8K Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-14

Immunovant, Inc. Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $891K +$324K +57.1% Apr 1, 2024 Mar 31, 2025 10-K 2025-05-29
2023 $567K +$558K +6200% Apr 1, 2023 Mar 31, 2024 10-K 2025-05-29
2022 $9K +$93K Apr 1, 2022 Mar 31, 2023 10-K 2025-05-29
2021 -$84K +$274K +76.5% Apr 1, 2021 Mar 31, 2022 10-K 2023-05-22
2020 -$358K -$455K -469% Apr 1, 2020 Mar 31, 2021 10-K 2022-06-08
2019 $97K +$78K +411% Apr 1, 2019 Mar 31, 2020 10-K 2021-06-01
2018 $19K Apr 1, 2018 Mar 31, 2019 10-K 2020-06-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.